Expert Review of Anticancer Therapy最新文献_第8页

An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer. talazoparib联合enzalutamide治疗转移性去势抵抗性前列腺癌的评价。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-25 DOI: 10.1080/14737140.2024.2445152

Riccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, Nicole Brighi, Daniela Montanari, Cristian Lolli, Sara Bleve, Margherita Piras, Giuseppe Palmieri, Mario Scartozzi, Panagiotis Paliogiannis, Ugo De Giorgi

{"title":"An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.","authors":"Riccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, Nicole Brighi, Daniela Montanari, Cristian Lolli, Sara Bleve, Margherita Piras, Giuseppe Palmieri, Mario Scartozzi, Panagiotis Paliogiannis, Ugo De Giorgi","doi":"10.1080/14737140.2024.2445152","DOIUrl":"10.1080/14737140.2024.2445152","url":null,"abstract":"Introduction: Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).Areas covered: This review evaluates the clinical efficacy, safety, and future potential of combining talazoparib, a potent PARPi, with enzalutamide, a strong androgen receptor (AR) antagonist. The combination of these two drugs was evaluated by the TALAPRO-2 trial, demonstrating significant improvement in radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients, particularly those with Homologous Recombination Repair (HRR) gene mutations such as BRCA1/2.Expert opinion: Emerging biomarkers like TMPRSS2-ERG and RB1 gene mutations have been recently reported as potential predictors of clinical outcome in the TALAPRO-2 all-comers population. Genomic markers for homologous recombination deficiency (HRD) are other potential drivers of response to PARPi/ARPI combination. Further investigation is needed to refine treatment strategies, including targeting non-HRR mutations, and to expand the role of this combination therapy in earlier stages of prostate cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1221-1227"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database. 老年患者（≥65岁）III-IVB期不能手术的口腔鳞状细胞癌（OCSCC）的治疗模式和结果：来自SEER数据库的一项调查研究。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-20 DOI: 10.1080/14737140.2024.2441872

Wangyan Zhong, Hang Yuan, Ting Li, Jiwei Mao, Xueying Jin, Dongping Wu

{"title":"Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database.","authors":"Wangyan Zhong, Hang Yuan, Ting Li, Jiwei Mao, Xueying Jin, Dongping Wu","doi":"10.1080/14737140.2024.2441872","DOIUrl":"10.1080/14737140.2024.2441872","url":null,"abstract":"Background: The aim of this retrospective study is to explore therapeutic patterns and survival outcomes for a cohort of older patients with stage III-IVB inoperable oral squamous cell carcinoma (OCSCC) patients receiving radiation therapy (RT) with or without chemotherapy (CT).Methods: This study conducted a retrospective review of 316 patients ≥ 65 aged years with stage III-IVB OCSCC from the Surveillance, Epidemiology, and End Results (SEER) registry (2010-2015). It compared RT alone (n = 109) with RT+CT (n = 207), utilizing Kaplan-Meier and Log-rank tests.Results: The estimated overall survival (OS) and cancer-specific survival (CSS) rates at 3 years were 20.6% and 25.9%, respectively. Both univariate and multivariate analyses identified that age and treatment option as independent prognosticators of OS and CSS. Further subgroup analyses showed that the combination of RT and CT significantly improved OS for all OCSCC patients, except those with hard palate tumors. Moreover, this combined treatment approach was linked to enhanced CSS in patients with gingival and tongue squamous cell carcinoma.Conclusion: RT+CT significantly enhanced survival in elderly OCSCC patients, particularly those with gingival and tongue cancers, but not in those with hard palate tumors.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1311-1318"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients. 释放生存优势：对新发 IV 期乳腺癌患者进行原发肿瘤切除术。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-11-15 DOI: 10.1080/14737140.2024.2428695

Dong Chen, Yue Wang, Yuancan Pan, Boran Zhang, Wentao Yao, Yu Peng, Ganlin Zhang, Xiaomin Wang

{"title":"Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients.","authors":"Dong Chen, Yue Wang, Yuancan Pan, Boran Zhang, Wentao Yao, Yu Peng, Ganlin Zhang, Xiaomin Wang","doi":"10.1080/14737140.2024.2428695","DOIUrl":"10.1080/14737140.2024.2428695","url":null,"abstract":"Background: For patients with de novo stage IV breast cancer (BC), the conditions under which the primary tumor resection (PTR) may offer benefit remain unclear.Methods: The SEER database provides treatment data for patients with de novo stage IV BC. We screened cases of metastatic BC diagnosed from 2010 to 2015, with primary endpoints of overall survival (OS) and cancer-specific survival (CSS).Results: 9252 patients with stage IV de novo BC were enrolled. For OS, median survival time (MST) was 38 months with systematic treatment (ST) compared to 52 months with ST plus PTR (p < 0.001). For CSS, MST was 38 months for ST versus 54 months for ST plus PTR (p < 0.001). The results of the Cox proportional hazards regression analysis regarding PTR, for OS: bone metastasis (aHR 0.664, 95%CI 0.583-0.756, p < 0.001); liver-lung metastasis (aHR 0.528, 95%CI 0.327-0.853, p = 0.009). For CSS: bone metastasis (aHR 0.655, 95%CI 0.571-0.751, p < 0.001); liver-lung metastasis (aHR 0.549, 95%CI 0.336-0.889, p = 0.017). Kaplan-Meier analysis indicated that in patients with bone metastases and liver-lung metastases, PTR could improve survival outcomes.Conclusion: Liver-lung metastases and bone metastases in patients with de novo stage IV BC could enhance both OS and CSS through PTR.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1303-1310"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer. 术后血清CEA预测hr阳性/ her2阴性早期乳腺癌的预后。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-19 DOI: 10.1080/14737140.2024.2443009

Gozde Kavgaci, Taha Koray Sahin, Tugcenur Muderrisoglu, Serez Ileri, Deniz Can Guven, Sercan Aksoy

{"title":"Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer.","authors":"Gozde Kavgaci, Taha Koray Sahin, Tugcenur Muderrisoglu, Serez Ileri, Deniz Can Guven, Sercan Aksoy","doi":"10.1080/14737140.2024.2443009","DOIUrl":"10.1080/14737140.2024.2443009","url":null,"abstract":"Background: The prognostic role of preoperative carcinoembryonic antigen (CEA) in breast cancer is recognized, but the impact of postoperative CEA levels on survival in early breast cancer is uncertain.Research design and methods: We conducted a retrospective study of 921 non-metastatic breast cancer patients treated at anonymized. Patients were categorized as normal (CEA ≤3 µg/L) or elevated (CEA >3 µg/L).Results: Elevated postoperative CEA levels were associated with shorter disease-free survival (DFS) (median, 174.6 vs. 239.8 months; hazard ratio (HR): 1.80; 95% confidence interval (CI): 1.27-2.56; p < 0.001) and overall survival (OS) (median, 174.6 vs. 261.1 months; HR:2.34; 95% CI: 1.59-3.45; p < 0.001). Elevated CEA was associated with shorter DFS (median, 174.6 months vs. not reached (NR); HR:2.30; 95% CI: 1.03-5.19; p = 0.043) and OS (NR vs. NR; HR: 2.81; 95% CI: 1.06-7.48; p = 0.039) in stage 1, shorter DFS (median, 239. 8 vs. 141.1 months; HR: 1.95; 95% CI: 1.28-2.98; p = 0.002) and OS (median, 169 vs. 261.1 months; HR: 2.56; 95% CI: 1.6-4.12; p < 0.001) in stage 2 and shorter OS (median, 65 vs. 183.1 months; HR: 3.25; 95% CI: 1.19-8.83; p = 0.021) in stage 3.Conclusions: Elevated postoperative CEA indicates worse DFS and OS in patients with HR-positive/HER2-negative early breast cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1319-1326"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Activation of ferritin light chain (FTL) by transcription factor salmonella pathogenicity island 1 modulates glycolysis to drive metastasis of ovarian cancer cells. 转录因子沙门氏菌致病性岛1激活铁蛋白轻链（FTL）调控糖酵解驱动卵巢癌细胞转移。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-16 DOI: 10.1080/14737140.2024.2439558

Chunxiang Li, Yubin Yang, Yuting Lin, Yingbin Lian, Dinglong Pan, Lin Lin, Luhong Li

{"title":"Activation of ferritin light chain (FTL) by transcription factor salmonella pathogenicity island 1 modulates glycolysis to drive metastasis of ovarian cancer cells.","authors":"Chunxiang Li, Yubin Yang, Yuting Lin, Yingbin Lian, Dinglong Pan, Lin Lin, Luhong Li","doi":"10.1080/14737140.2024.2439558","DOIUrl":"10.1080/14737140.2024.2439558","url":null,"abstract":"Background: Ovarian cancer (OC) is the most lethal gynecological cancer often diagnosed at an advanced stage due to a lack of effective biomarkers. Ferritin light chain (FTL) is implicated in the development of various cancers, but its impact on OC remains unknown.Research design and methods: Bioinformatics methods were utilized to analyze FTL. Quantitative real-time polymerase chain reaction, western blot, and immunohistochemistry were employed for expression detection, and cell counting kit- 8, and transwell assays were for cell biological functions assessment. Extracellular acidification rate, oxygen consumption rate, and glycolytic metabolite contents were measured. Dual-luciferase and chromatin immunoprecipitation assay validated binding relationship. Xenografted tumor models in nude mice verified the role of FTL in vivo.Results: Cell function experiments revealed that FTL facilitated proliferation, migration, and invasion of OC cells. Rescue experiments unveiled that 2-Deoxy-D-glucose attenuated stimulation on OC cell metastasis and glycolysis by FTL overexpression. Salmonella pathogenicity island 1 (SPI1) up-regulated FTL expression to promote glycolysis and metastasis. FTL knockdown inhibited tumor growth and suppressed glycolysis and cell metastasis in vivo, while SPI1 overexpression attenuated these effects.Conclusions: This study demonstrated pro-metastatic mechanisms of transcription factor SPI1/FTL axis in OC and suggested it as a potential target for treating OC metastasis.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1271-1282"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging therapeutics in the management of tenosynovial giant cell tumor (TGCT). 腱鞘巨细胞瘤（TGCT）的新兴治疗方法。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-22 DOI: 10.1080/14737140.2024.2445754

Victoria Wytiaz, Geoffrey Siegel, Rashmi Chugh

{"title":"Emerging therapeutics in the management of tenosynovial giant cell tumor (TGCT).","authors":"Victoria Wytiaz, Geoffrey Siegel, Rashmi Chugh","doi":"10.1080/14737140.2024.2445754","DOIUrl":"10.1080/14737140.2024.2445754","url":null,"abstract":"Introduction: Tenosynovial giant cell tumors (TGCTs) are locally aggressive mesenchymal neoplasms that often occur in younger patients and cause long-term disability. Surgical management remains the standard of care, but with high risks of surgical morbidity, systemic treatment options are important to consider, particularly in diffuse disease. Improved understanding of the molecular pathogenesis of TGCTs has led to exciting developments in this arena.Areas covered: This review aims to provide historical context for systemic treatments for patients with TGCTs with a focus on the diffuse subtype (DT-TGCT) while exploring the more recently available treatments in depth. Current literature on TGCTs and therapy was reviewed and summarized by a comprehensive search of MEDLINE (1/1/1989-11/30/2024). We also suggest directions for future investigation in the systemic treatment space for TGCT with a goal to alleviate symptoms and improve quality of life while minimizing treatment-related toxicity.Expert opinion: Advances in the understanding of the molecular pathogenesis of TGCT has led to systemic therapies targeting the CSF1 receptor (CSF1R), including the first FDA approval in this space of pexidartinib. These developments provide the foundation for further investigation into additional treatments, optimal sequencing, and duration of therapies for patients with symptoms and reduced functionality secondary to TGCT.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1229-1236"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters. 利用免疫组化和临床参数开发宫颈上皮内瘤术后复发预测提名图。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-11-04 DOI: 10.1080/14737140.2024.2423681

Shikang Qiu, Huihui Jiang, Qiannan Wang, Limin Feng

{"title":"Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters.","authors":"Shikang Qiu, Huihui Jiang, Qiannan Wang, Limin Feng","doi":"10.1080/14737140.2024.2423681","DOIUrl":"10.1080/14737140.2024.2423681","url":null,"abstract":"Background: We aimed to develop a nomogram to predict abnormal follow-up results of co-testing for cytology and human papillomavirus (HPV) in cervical intraepithelial neoplasia (CIN) patients after conization.Research design and methods: Two hundred sixty-three patients initially diagnosed as CIN2+ were recruited. Data on immunohistochemical (IHC) staining scores, along with demographic and clinical information were collected. Using least absolute shrinkage and selection operator (LASSO) regression analysis, variables were identified for inclusion. A predict model and nomogram were developed through multi-factor logistic regression. The goodness-of-fit test was applied across different cohorts to construct the calibration curve of the model, and the predictive effect was evaluated by the receiver operating characteristic curve. Decision curve analysis was performed to determine the net benefit.Results: Five predictor variables, including protein expression score, vaginal infection, HPV coinfection, and cone height were screened and plotted as a nomogram. The calibration curves showed a good fit. The area under the curve of the model was 0.835 for the training cohort and 0.728 for the internal test cohort. The decision curve analysis indicated that the nomogram provides significant net advantages for clinical use.Conclusion: A practical nomogram predict model was developed to predict abnormal follow-up outcomes in CINs after conization.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1261-1269"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care. 多学科团队在优化非肌层浸润性膀胱癌治疗中不断发展的作用。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-10-18 DOI: 10.1080/14737140.2024.2417768

Amanda A Myers, Alexis R Steinmetz, Ashish M Kamat

{"title":"The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care.","authors":"Amanda A Myers, Alexis R Steinmetz, Ashish M Kamat","doi":"10.1080/14737140.2024.2417768","DOIUrl":"10.1080/14737140.2024.2417768","url":null,"abstract":"Introduction: Non-muscle invasive bladder cancer (NMIBC) represents a significant portion of bladder cancer cases and imposes a substantial economic burden, stemming from both direct treatment costs and long-term surveillance. As the treatment landscape evolves with advances in immunotherapy and targeted therapies, a multidisciplinary approach to management is increasingly crucial for optimizing patient outcomes and resource utilization.Areas covered: A PubMed search from 2010 to 15 June 2024 was conducted. This review examines the evolving role of multidisciplinary team (MDT) care in NMIBC management. It explores the potential benefits of MDT care, including improved risk stratification and personalized treatment plans, while acknowledging the challenges to implementation and proposing strategies to overcome them.Expert opinion: With a growing understanding of NMIBC and expanding therapeutic options, MDT care is pivotal in navigating patient care and maximizing outcomes. Strategic planning and collaborative efforts will facilitate the broader adoption of MDT care, enhancing the value of NMIBC treatment. MDT care holds promise for personalized, effective, and cost-efficient care for patients with NMIBC in the future.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1203-1208"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Arguments for and against extending the interval between colonoscopies following negative results in colorectal cancer screening. 支持和反对在结直肠癌筛查阴性结果后延长结肠镜检查间隔的争论。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-12 DOI: 10.1080/14737140.2024.2438074

Michael Hoffmeister, Thomas Heisser, Hermann Brenner

引用次数: 0

Practical insights into bispecific antibody therapy in multiple myeloma. 双特异性抗体治疗多发性骨髓瘤的实践见解。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2025-01-12 DOI: 10.1080/14737140.2024.2445145

Yumena Kawasaki, Sara Winger, Naseem Esteghamat, Aaron Rosenberg, Ryan Beechinor

{"title":"Practical insights into bispecific antibody therapy in multiple myeloma.","authors":"Yumena Kawasaki, Sara Winger, Naseem Esteghamat, Aaron Rosenberg, Ryan Beechinor","doi":"10.1080/14737140.2024.2445145","DOIUrl":"10.1080/14737140.2024.2445145","url":null,"abstract":"Introduction: The rise of recent novel therapies teclistamab, elranatamab, and talquetamab for the treatment of relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area with significant clinical implications that require exploration and evaluation.Areas covered: The current review highlights the clinical trial data, safety endpoints, and practical administration considerations for the bispecific therapies currently used in multiple myeloma. This article reviewed the efficacy and safety results between the three different bispecifics, and the differences in dosing and monitoring requirements. Adverse event management for the bispecific antibodies will be explored including the need for antimicrobial prophylaxis, premedication, and IVIG replacement. Future considerations for widespread bispecific administration and ongoing clinical trials are discussed.Expert opinion: Practical considerations for bispecific administration such as hospitalization requirements, monitoring of adverse events, and medication considerations are emphasized. Future directions and clinical implications regarding the pivotal role of these agents will be discussed.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1209-1219"},"PeriodicalIF":2.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0